Merimepodib

Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.

Product Specifications

CAS Number

[198821-22-6]

Product Name Alternative

VX-497; MMPD

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Dengue Virus; Flavivirus; HBV; HCV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Merimepodib.html

Purity

99.64

Solubility

DMSO : ≥ 31 mg/mL

Smiles

O=C(O[C@@H]1COCC1)NCC2=CC=CC(NC(NC3=CC=C(C4=CN=CO4)C(OC)=C3)=O)=C2

Molecular Formula

C23H24N4O6

Molecular Weight

452.46

Precautions

H302, H315, H319, H335

References & Citations

[1]Jain J, et al. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90 (5) :625-37.|[2]Markland W, et al. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother. 2000 Apr;44 (4) :859-66.|[3]Decker CJ, et al. The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice. Drugs Exp Clin Res. 2001;27 (3) :89-95.